The lack of new antibiotics and the rise in drug resistance have rendered some serious and life-threatening infections untreatable, and the health care community is searching for ways to bring innovative new drugs to patients whose treatment options are limited or nonexistent.
On Jan. 31, 2013, The Pew Charitable Trusts hosted a one-day conference, "A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations." Pew brought together government regulators, infectious disease physicians, public health specialists, pharmacists, pharmaceutical company representatives, and payors to weigh the merits of a proposed new Food and Drug Administration approval mechanism: a limited population regulatory pathway. The proposal promises to bring urgently needed medicines to the sickest patients by reducing some of the economic and regulatory barriers to antibiotic innovation.
Some general themes emerged from the conference:
- Payors, health care providers, and pharmaceutical companies generally supported the concept of a limited population regulatory pathway.
- The pathway could increase the feasibility and lower the costs of clinical trials for high-need antibiotics.
- Limited population antibiotics would likely command premium pricing, which could provide a reasonable return on investment for antibiotic developers.
- Premium pricing could ensure that limited population antibiotics are not used indiscriminately, thus preserving the effectiveness of these critical drugs over time.
- A special designation or labeling alone would not curtail unnecessary use of the limited population antibiotics, but could signal that these drugs are different from other antibiotics and should be treated accordingly.
- Strict restrictions or penalties on the use of limited population antibiotics were not recommended, but all participants agreed that stewardship—the proper management and data-driven use of these drugs — would be important for success of the pathway.
For more detail, download and read the event proceedings transcript (PDF file).
On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the Food and Drug Administration Safety and Innovation Act. This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.More info
Last spring, Arjun Srinivasan, an associate director of the CDC, delivered a presentation to state health officials with some alarming information. Before the year 2000, he said, it was rare to find cases of bacteria resistant to carbapenems, a class of powerful, last-resort antibiotics. But by February 2013 they had been seen in almost every state. On March 5, Thomas Frieden, director of the CDC, issued a public warning about “nightmare” bacteria, a family of germs known as CREs. They can kill up to half the patients who get bloodstream infections from them, resist most or all antibiotics and spread resistance to other strains.More info
"On Sept 16, the US Centers for Disease Control and Prevention (CDC) released its report Antibiotic Resistance Threats in the United States, 2013 —their first ever reporton this subject. From the outset the tone is clear: in his foreword, Tom Frieden, director of the CDC, states that "antimicrobial resistance is one of our most serious health threats. Infections from resistant bacteria are now too common." The stated aim of this report is to increase awareness of the threat resistance poses and to encourage immediat e action to address this threat."More info
"A recent report from the Centers for Disease Control and Prevention is adding urgency to an issue lawmakers from both parties say they want to address: the rise of bacteria that are resistant to antibiotics."More info